Gilead pays Parion Phase I development milestone
This article was originally published in Scrip
Gilead Sciencesis to pay Parion Sciences a $5 million milestone after beginning a Phase I safety trial of GS9411. The epithelial sodium channel (ENaC) blocker, previously known as P-680, is an investigational compound designed to increase airway hydration for the treatment of pulmonary diseases. Gilead acquired the worldwide commercialisation rights to GS9411 for the treatment of pulmonary diseases, including cystic fibrosis (CF), chronic obstructive pulmonary disease and non-CF bronchiectasis, in August last year. Gilead will be responsible for the product's further primary development. The two companies are working together to develop other ENaC blocker-based drug candidates using Parion's ENaC-based chemistry platform.